Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients

Blood Purification

Volumn 26, Issue 4, 2008, Pages 317-321

  Eleftheriadis, Theodoros ^a   Kartsios, Charalambos ^b   Yiannaki, Efi ^b   Kazila, Polizo ^b   Antoniadi, Georgia ^a   Liakopoulos, Vassilios ^a   Markala, Dimitra ^b  

^a General District Hospital of Serres   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Hemodialysis; Immune response; Inflammation; Natural killer cell; Zeta chain

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CD16 ANTIGEN; CD3 ANTIGEN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL SUBPOPULATION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; ZETA CHAIN;

AGED; ANTIGENS, CD3; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IGG; RENAL DIALYSIS;

EID: 48349142853     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000130068     Document Type: Article

References (28)

1. O'Connor GM, Hart OM, Gardiner CM: Putting the natural killer cell in its place. Immunology 2006;117:1-10.
2. Maghazachi AA: Insights into seven and single transmembrane-spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol Rev 2005;57:339-357.
3. Kay NE, Raij L: Differential effect of hemodialysis membranes on human lymphocyte natural killer function. Artif Organs 1987;11:165-167.
4. Asaka M, Iida H, Izumino K, Sasayama S: Depressed natural killer cell activity in uremia. Evidence for immunosuppressive factor in uremic sera. Nephron 1988;49:291-295.
5. Cala S, Mazuran R, Kordic D: Negative effect of uraemia and cuprophane hemodialysis on natural killer cells. Nephrol Dial Transplant 1990;5:437-440.
6. Quesada JM, Serrano I, Borrego F, Martin A, Pena J, Solana R: Calcitriol effect on natural killer cells from hemodialyzed and normal subjects. Calcif Tissue Int 1995;56:113-117.
7. Gascon A, Orfao A, Lerma JL, Ciudad J, Lopez A, Hernandez MD, Tabernero JM: Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients. Am J Kidney Dis 1996;27:373-379.
8. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-99.
9. Sarnak M, Jaber B: Mortality caused by sepsis in patients with end-stage renal disease compared with the normal population. Kidney Int 2000;58:1758-1764.
10. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
11. Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16:38-52.
12. Baniyash M: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004;4:675-687.
13. Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM: Gene expression of interleukin-1 beta during hemodialysis. Kidney Int 1993;43:712-721.
14. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995;47:559-565.
15. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-636.
16. Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
17. Schindler R, Lonnemann G, Schaffer J, Shaldon S, Koch KM, Krautzig S: The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. Nephron 1994;68:229-233.
18. Girndt M, Heisel O, Kohler H: Influence of dialysis with polyamide vs. haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999;14:676-682.
19. Varela MP, Kimmel PL, Phillips TM, Mishkin GJ, Lew SQ, Bosch JP: Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purif 2001;19:370-379.
20. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovannini L, Tetta C, Palla R: C reactive protein in patients with chronic renal diseases. Ren Fail 2001;23:551-562.
21. Kushner I: Regulation of the acute phase response by cytokines. Perspect Biol Med 1993;36:611-622.
22. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-960.
23. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM: Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care 2004;7:427-434.
24. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
25. Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, Pines M, Pikarsky E, Baniyash M: A common pathway mediated through Toll-like receptors leads to T and natural killer cell immunosuppression. Blood 2008;111:1437-1447.
26. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26:1308-1313.
27. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L -arginine consumption by macrophages modulates the expression of CD3 zeta-chain in T lymphocytes. J Immunol 2003;171:1232-1239.
28. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-3048.